Status:
COMPLETED
Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer
Lead Sponsor:
Sanofi
Conditions:
Rectal Neoplasms
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Primary objective: \- To evaluate the rate of responses to neoadjuvant therapy + radiotherapy Secondary objective: \- tolerability (toxicity) and time to progression
Eligibility Criteria
Inclusion
- The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
- Main criteria are listed hereafter:
- Patients with measurable, histologically proven rectal cancer.
- No history of previous malignancy but adequately treated skin / cervical cancer.
- Adequate haematological, renal and liver function.
Exclusion
- No cardiopulmonary insufficiency or coronary disease. No sensory neuropathy prior to study.
Key Trial Info
Start Date :
July 1 2001
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00403624
Start Date
July 1 2001
End Date
November 1 2005
Last Update
August 27 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.